psychedelics – Page 3

Norpsilocin: freebase and fumarate salt

mycolabadmin

Researchers determined the crystal structures of norpsilocin, a naturally occurring compound found in magic mushrooms that is chemically similar to psilocin. This work is important because norpsilocin appears to be as potent as psilocin at serotonin receptors and may contribute to the therapeutic effects of magic mushroom extracts. By obtaining pure crystalline forms and understanding the compound’s structure, scientists can better study its properties and potential medical applications for treating conditions like depression and anxiety.

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

mycolabadmin

This comprehensive review examines how scientists use advanced imaging techniques like PET and SPECT scans to study how hallucinogenic drugs such as LSD and psilocybin interact with the brain. The research shows these drugs primarily bind to serotonin receptors, particularly the 5-HT2A subtype, which appear responsible for producing hallucinations. While scientific understanding of hallucinogen mechanisms has advanced significantly, there is still much to learn about their complete effects on brain chemistry and their potential therapeutic applications.

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT)

mycolabadmin

This study used computer models of brain activity to understand how the psychedelic drug DMT rapidly changes how the brain works during an acute experience. Researchers found that DMT pushes brain dynamics into a special state where the brain becomes hypersensitive to small changes or stimuli. This heightened sensitivity is strongest in brain regions rich in serotonin receptors and matches the expected timing of the drug’s effects, suggesting that brief psychedelic experiences may create lasting changes in the brain through this temporary destabilization window.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study

mycolabadmin

Researchers studied how ayahuasca affects memory in experienced Santo Daime church members who use it regularly. Surprisingly, instead of impairing memory like other psychedelics typically do, ayahuasca enhanced people’s ability to remember details of events they witnessed. Importantly, the drug did not make people more susceptible to false memories or memory distortions, even though the entire study occurred while participants were under its acute effects.

Moral enhancement and cheapened achievement: Psychedelics, virtual reality and AI

mycolabadmin

This paper examines whether using drugs or technology to become a more moral person cheapens the value of that achievement, similar to debates about ‘cheating’ through cognitive enhancers. The authors argue that realistic applications of psychedelics, virtual reality, and AI—when used to facilitate rather than replace moral learning—can actually preserve what makes moral improvement valuable: our own effort, reflection, and engagement with moral reasons.

Psilocybin Does Not Induce Conditioned Place Preference, But Modifies Behavioral Patterns in Sprague-Dawley Rats

mycolabadmin

Researchers tested whether psilocybin, a compound found in magic mushrooms, could be addictive by examining reward-seeking behavior in rats. The study found that psilocybin did not create rewarding effects that would typically lead to addiction, and only temporarily changed specific behaviors like head-twitching and grooming while the drug was active. These findings suggest that psilocybin has a low addiction potential and may be safe for therapeutic use in treating mental health conditions.

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

mycolabadmin

This study examined how psilocybin works to reduce anxiety in mice by investigating the role of stress hormones, particularly corticosterone. Researchers found that psilocybin causes a temporary spike in corticosterone levels that is essential for its anxiety-reducing effects hours after administration. Interestingly, other interventions that increase corticosterone levels also produced similar anxiety-reducing effects, suggesting the stress hormone response itself drives the therapeutic benefit rather than psilocybin’s psychedelic properties alone. These findings suggest that measuring cortisol levels in human patients receiving psilocybin therapy could help explain and optimize therapeutic outcomes.

Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes

mycolabadmin

This study surveyed over 250 million representative American adults about their use of psychedelic mushrooms. Researchers found that about 1.7% of US adults used psychedelic mushrooms in the past year, primarily for general mental health and well-being. Interestingly, those who used them reported higher levels of depression and anxiety, suggesting people with mental health challenges may be self-treating with mushrooms. The findings highlight the need for evidence-based guidelines as more Americans explore psychedelics for health purposes.

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

mycolabadmin

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Research Topic: psychedelics